Is Red Light Therapy Safe for Your Thyroid?

Red light therapy, more formally called photobiomodulation, is generally safe for the thyroid gland based on the available clinical evidence, though the research base is still small and mostly comes from a handful of research groups. Studies that deliberately targeted the thyroid to treat autoimmune thyroiditis reported no serious adverse effects, and a study that tracked thyroid function in people using an LED device on the neck purely for skin rejuvenation found zero measurable changes in thyroid hormones or gland structure over six months. The picture gets more complicated when you factor in pre-existing thyroid nodules, thyroid cancer, and the wide variation in devices people actually use at home.

How Red and Near-Infrared Light Interact with Thyroid Tissue

The thyroid sits just below the skin of the neck, which makes it unusually accessible to light compared with most internal organs. Red light (roughly 630–660 nm) and near-infrared light (roughly 800–850 nm) can penetrate soft tissue to varying depths, with near-infrared wavelengths reaching further than red ones because tissue scatters and absorbs them less aggressively.¹ The thyroid’s shallow position means even modest devices can deliver photons to the gland itself.

Once photons reach living cells, the proposed mechanism centers on an enzyme in mitochondria called cytochrome c oxidase. Light absorption by this enzyme appears to influence energy production, membrane potential, and the cell’s internal balance of reactive oxygen species.² In the thyroid specifically, this cascade is thought to reduce local inflammation and improve blood supply, which are relevant because the most common thyroid condition treated with photobiomodulation is Hashimoto’s thyroiditis, an autoimmune disease that progressively inflames and damages the gland.

The Hashimoto’s Thyroiditis Trials

Most of the clinical research on red light therapy and the thyroid has focused on Hashimoto’s thyroiditis (also called chronic autoimmune thyroiditis). A randomized, placebo-controlled trial in Brazil applied low-level laser therapy twice a week for ten sessions to the thyroid glands of patients with hypothyroidism caused by Hashimoto’s. At follow-up, patients who received the real laser treatment required a substantially lower dose of levothyroxine medication compared with those who received sham treatment. The laser group also showed lower levels of thyroid peroxidase antibodies, a marker of autoimmune attack on the gland, and ultrasound imaging revealed improved tissue echogenicity, suggesting healthier-looking thyroid tissue.³

A long-term follow-up study tracked similar outcomes over a longer period. Patients in the laser group continued to need less levothyroxine than the placebo group, and the rate of thyroid nodule development was similar between groups, with all biopsied nodules classified as benign.⁴ A separate trial combined photobiomodulation with nutritional supplements in Hashimoto’s patients and found that the combination group had greater improvements in thyroid-stimulating hormone levels, antibody levels, levothyroxine dose, and several body composition measures compared with supplements alone.⁵

Importantly, none of these trials reported significant adverse effects on the thyroid gland itself. No patient developed hyperthyroidism (an overactive thyroid) from the treatment, and no malignant nodules appeared. The evidence is encouraging, but it comes from a small number of studies, several of which share overlapping research teams in Brazil. No large, multi-center trial has been published, and no endocrinology professional society has formally endorsed photobiomodulation for Hashimoto’s.

Blood Flow and Tissue Changes on Ultrasound

One of the more concrete ways researchers have tracked what red light therapy does to the thyroid is through Doppler ultrasound, which maps blood flow in real time. In patients with autoimmune hypothyroidism, laser therapy was associated with improved vascularization of the thyroid tissue and increased blood flow velocity through the inferior thyroid artery, compared with a placebo group.⁶ The finding matters because chronic autoimmune thyroiditis gradually destroys thyroid tissue and reduces its blood supply. If photobiomodulation genuinely restores some of that vascular function, it could partly explain why treated patients maintain thyroid output on lower medication doses.

That said, improved blood flow in a damaged gland is a different proposition from changing blood flow in a healthy one. In people with normal thyroid function, there is no evidence that red light therapy pushes the gland into overproduction or causes structural changes, a point reinforced by the neck rejuvenation study discussed below.

When the Thyroid Is Just a Bystander

Many people using red light therapy near the neck are not targeting their thyroid at all. They might be treating neck wrinkles, jaw pain, or general skin rejuvenation. For these users, the relevant safety question is whether incidental light exposure harms a healthy thyroid that happens to be in the path of the beam.

A study designed specifically to answer this question had participants use an LED device on the neck for skin rejuvenation over 16 weeks, followed by an 8-week monitoring period after they stopped. Throughout the entire study, thyroid hormone levels, parathyroid hormone levels, and thyroid antibody levels showed no meaningful changes. Ultrasound measurements of gland volume, tissue echogenicity, lymph nodes, blood flow, and any pre-existing incidental nodules likewise remained stable.⁷ The researchers concluded that long-term LED use on the neck was safe for the adjacent thyroid and parathyroid glands. For people with no pre-existing thyroid condition, this is probably the most directly reassuring finding in the literature.

Oxidative Stress and Quality of Life

Beyond hormone levels and ultrasound images, a more recent randomized controlled trial looked at oxidative stress markers and how patients with Hashimoto’s felt day to day. Patients who received active laser treatment twice a week for three weeks showed higher glutathione levels, an important antioxidant, compared to a sham group. They also reported better quality of life scores.⁸ The treatment period was short, so whether those benefits persist is unclear, but the absence of adverse events in yet another controlled trial adds to the safety profile.

Quality-of-life improvements are worth noting because Hashimoto’s patients frequently report brain fog, fatigue, and mood issues that do not always correlate neatly with thyroid lab values. Whether the quality-of-life boost comes from genuine biological changes, a placebo response, or some combination is hard to untangle in a small study, but the safety side remained clean.

The Cancer Question

The most anxiety-provoking concern for anyone shining light on their neck is whether it could promote thyroid cancer growth. This is a legitimate question, and the answer is more nuanced than a simple all-clear.

A systematic review of photobiomodulation safety in oncology, covering both animal and human studies, concluded that the therapy appears safe with respect to tumor growth when used at standard clinical parameters. Human studies, including those involving head and neck cancer patients receiving photobiomodulation to manage treatment side effects, did not show evidence of tumor promotion.⁹

A separate systematic review focused on skin rejuvenation examined preclinical studies more closely. Of six animal studies that investigated tumor growth, three found no effect on tumors, one found that photobiomodulation actually inhibited tumor growth, and two found that it increased tumor growth. The two studies showing increased growth had unusual features: one used immunocompromised mice hosting human tumors, and the other used an energy density far above anything used clinically. One experiment involving anaplastic thyroid carcinoma (an extremely aggressive thyroid cancer) in immunocompromised mice did show increases in tumor size and markers associated with tumor blood vessel growth.¹⁰

On the other side, a research group developing a wearable photobiomodulation device found that blue light at 465 nm could inhibit the proliferation of papillary thyroid cancer cells and suppress tumor growth in mouse models without adverse effects.¹¹ That study used a very different wavelength than most consumer red light therapy devices, so the finding does not directly reassure people using standard red or near-infrared panels. Still, it demonstrates that light-thyroid interactions are wavelength-dependent, and not all of them push toward growth.

The practical takeaway: if you have been diagnosed with thyroid cancer or have suspicious thyroid nodules awaiting biopsy, treating the neck area with red light therapy is not supported by current evidence and carries theoretical risk. The animal data showing tumor promotion at extreme doses, and specifically in anaplastic thyroid carcinoma, is enough reason for caution. For people with no known thyroid malignancy, the clinical studies to date have not shown evidence of cancer initiation or nodule promotion.

Thermal Safety and Skin Reactions

Excessive tissue heating is a concern with any device that delivers energy to the body, but the power densities used in photobiomodulation are far below those that cause thermal damage. A study measuring skin temperature during concurrent use of super-pulsed lasers and pulsed red and infrared LEDs found no significant temperature increases across different skin colors, ages, or genders.¹² The thyroid is protected by several millimeters of skin, subcutaneous tissue, and muscle, so if the skin surface is not heating up, the gland beneath it is not either.

Localized skin reactions from red light alone are rare and mild when they occur. A study evaluating red light applied to neck skin for photorejuvenation reported no significant changes in redness or erythema in the group receiving red light only (as opposed to a photodynamic therapy group that used a light-activated chemical).¹³ Burns from red light therapy devices are occasionally reported anecdotally but are almost always linked to falling asleep in contact with a high-power device or using a device far outside recommended exposure times.

Eye Safety During Neck Treatments

When treating the neck, your eyes are close to the light source. The primary safety hazard with photobiomodulation devices remains ocular. Laser-based devices especially can cause retinal damage if a beam enters the eye, though most consumer devices use LEDs that emit divergent (non-focused) beams, reducing the risk at even short distances. Safety guidelines recommend that everyone present during treatment wear appropriate protective eyewear and that beams never be aimed toward the eyes.¹⁴ This is not a thyroid-specific concern, but it is the most concrete physical risk during a session aimed at the neck.

Can Light Applied Somewhere Else Affect Your Thyroid?

Some people wonder whether red light therapy applied to a distant body part, say the jaw after dental work or a knee for pain, could indirectly change thyroid function through systemic effects. The evidence here is thin and mixed. One animal study found that low-level laser therapy applied to the jaw of rabbits influenced thyroid function, though the hormone values stayed within the normal range.¹⁵ Another rabbit study using a different protocol found no effect on thyroid hormones at all.¹⁶

These are animal studies with small sample sizes and different laser protocols, so drawing firm conclusions for humans would be premature. But the fact that one study found a measurable (if clinically insignificant) effect on a gland that was not even being targeted suggests that photobiomodulation has systemic biological effects beyond the treatment site. For people with well-controlled thyroid conditions who are receiving light therapy elsewhere on the body, this is not a reason to panic, but it is a reason to keep monitoring thyroid labs on your usual schedule.

Home Devices Versus Clinical Equipment

The studies cited above used carefully calibrated clinical-grade laser or LED equipment with known wavelengths, power densities, and treatment durations. Consumer red light therapy panels and handheld devices vary enormously. Some are underpowered to the point of being biologically inert. Others use wavelengths outside the therapeutic window or lack independent verification of their specifications. A few higher-end consumer panels deliver power densities comparable to clinical devices.

The LED neck rejuvenation device tested for thyroid safety was a consumer-type product, and its results were reassuring: no thyroid changes over nearly six months of regular use.⁷ But that finding applies to one specific device at one specific set of parameters. A different device at much higher power, held closer to the skin, or used for much longer sessions has not been tested in the same way. The common refrain in photobiomodulation research is that dose matters enormously, and more is not always better. Very high energy densities can inhibit rather than stimulate cellular activity, a concept researchers call the biphasic dose response.

If you are using a home device on or near the neck, sticking to manufacturer-recommended treatment times and distances is the most practical precaution. If the device does not specify parameters for neck use, keeping sessions short and the device at arm’s length from the thyroid area is a reasonable default.

Who Should Be Cautious

The safety evidence is most reassuring for two groups: people with healthy thyroids who happen to be using red light therapy on the neck for cosmetic or musculoskeletal reasons, and people with stable Hashimoto’s thyroiditis who are exploring photobiomodulation under clinical supervision. The evidence is least reassuring, or simply absent, for a few specific situations:

• Active thyroid cancer: The animal data on anaplastic thyroid carcinoma showing possible tumor promotion at high doses, and the general uncertainty about light-tumor interactions, make this a clear case for avoidance unless directed by an oncologist.
• Undiagnosed nodules: If you have a thyroid nodule that has not been biopsied or characterized, adding an uncontrolled growth stimulus is not a risk worth taking.
• Graves’ disease: None of the thyroid-focused photobiomodulation trials enrolled patients with hyperthyroidism. The mechanism that improves function in an underactive gland could theoretically worsen overactivity, though this has not been studied.
• Pregnancy: Thyroid function fluctuates during pregnancy, and no photobiomodulation safety data exists for pregnant people targeting the thyroid area.

For people in these categories, the honest answer is that we do not have enough data to say the therapy is safe. The absence of evidence of harm is not the same as evidence of safety, and the thyroid’s role in regulating metabolism, heart rate, and development makes erring on the side of caution sensible.

Why the Research Remains So Limited

Given the rising consumer interest in red light therapy and the prevalence of thyroid conditions, the research base is strikingly thin. The largest randomized trials on photobiomodulation and the thyroid have enrolled fewer than 50 patients. Much of the work originates from one research group in Brazil, which means the findings have not been independently replicated by groups with different equipment, protocols, and patient populations. The Hashimoto’s trials used specific laser devices applied by trained clinicians in controlled settings, conditions that are difficult to replicate with a panel bought online.

Photobiomodulation also faces a basic funding challenge. The devices are relatively inexpensive, unpatentable in their general form, and sit outside the conventional pharmaceutical pipeline, so there is little commercial incentive to run the large, expensive trials that would produce definitive safety and efficacy data. Endocrinology guidelines from major professional societies do not mention photobiomodulation for thyroid conditions, reflecting both the small evidence base and the field’s conservative approach to recommending treatments without robust trial data. Researchers publishing in this area consistently call for larger, multicenter trials, and until those materialize, the safety conclusions remain provisional.